Application of bulleyaconitine A

A technology of clathrin and medicine, which is applied in the application field of clathrate to achieve the effects of exact curative effect, inhibiting itching and controlling recurrent attacks

Active Publication Date: 2019-03-12
YUNNAN HAOPY PHARM LTD
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there has been no relevant report on the effect and efficacy of aconitin in the treatment of pruritus; at the same time, the aconitin drug monomer is an active drug extracted from traditional Chinese medicine, which has good safety and relatively low side effects. Fewer, non-addictive features

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bulleyaconitine A
  • Application of bulleyaconitine A
  • Application of bulleyaconitine A

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Purpose:

[0035] Studies over the years have shown that itching is mainly conducted by two types of C fibers, one sensitive to histamine and the other sensitive to chloroquine. Therefore, the animal scratching response induced by subcutaneous injection of histamine or chloroquine is an internationally recognized model of acute pruritus. The purpose of the present invention is to explore whether orthoacine (BLA) can inhibit the acute itching caused by histamine and chloroquine.

[0036] Experimental materials and methods:

[0037]6-8 week C57 mice (body weight 17-20 g, the animals were obtained from the Experimental Animal Center of Sun Yat-Sen University) were used in the experiment. The mice were randomly divided into four groups: solvent+histamine control group, BLA+histamine group, solvent+chloroquine control group and BLA+chloroquine group. Three days before the start of the experiment, the nape of the neck was shaved (at least 3 x 5 cm) under brief anesthesia w...

Embodiment 2

[0054] The application of the aconitin of the present invention in neuropathic pruritus can make the aconitin into different dosage forms for use. To be specific, aconitin can be made into dosage forms including capsules, tablets or granules+granules. Concrete medicine can include aconitin and other pharmaceutically acceptable carriers, and the dosage of each component in the medicine can be adjusted according to the proportioning requirements of the components in the pharmaceutical preparation, and the effective content of aconitin can also be adjusted. It can be calculated according to the requirements of conventional dosage forms such as different dosage forms, 0.01375mg / kg to 0.055mg / kg body weight / d described in Example 1, this example only provides a reference value range here, and is not specifically limited. To further illustrate, the pharmaceutically acceptable carrier can use deodorants, fillers, disintegrants, coloring agents and thickeners, etc. Low-flavoring agen...

Embodiment 3

[0056] A tablet containing aconitin, each film-coated tablet containing 0.275 mg aconitin and 130 mg of auxiliary materials. Dissolve aconitin with food grade or pharmaceutical grade ethanol; mix excipients lactose 20mg, powdered sugar 25mg, microcrystalline cellulose 40mg and hydroxypropyl cellulose 10mg, then add aconitin ethanol and mix, then add Appropriate amount of purified water is mixed to make a soft material, which is then made into granules and then dried. Magnesium stearate and sodium carboxymethyl starch are added to the dried granules, pressed into tablets for a few minutes, and then coated with film.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicines, and particularly relates to application of bulleyaconitine A. Bulleyaconitine A is applied to treating pruritus cutanea, and the situation that drugs such as antihistamines and hormones can produce unwelcome reactions so that the drugs cannot be applied for a long time and can only be applied intermittently, and thus pruritus recurs is avoided. Bulleyaconitine A has the positive effects when being applied to treating pruritus cutanea, has no liver and kidney toxicity side effects, can be applied for a long time, can control pruritus cutanea notto recur, and can avoid pachulosis and lichenification caused by unconscious scratching and secondary lesion such as eczema, neurodermatitis and prurigo nodularis. Bulleyaconitine A is applied to treating pruritus cutanea, solves the problem that a patient is troubled a lot by pruritus so that sleeping and resting of the patient are affected seriously because pruritus recurs at night, and effectively relieves the pain and mental stress of the patient and the family brought by pruritus.

Description

technical field [0001] The invention relates to the field of medicaments, in particular to the application of aconitin. Background technique [0002] Skin pruritus, also known as pruritus, is a common sensory phenomenon related to the desire to scratch. There are various causes of skin pruritus. Clinically, many diseases can cause skin pruritus, and its etiology is also complicated. Those who have skin itching without primary skin eruption are called pruritus or pruritus. Skin pruritus can be divided into generalized skin pruritus and localized skin pruritus according to its diseased part. The cause of disease of systemic dermatosis is mostly relevant with body metabolic disorder and endocrine abnormality. Common reasons are as follows. Senile skin pruritus is due to the hypofunction of sebaceous glands in the elderly, poor peripheral circulation, and weakened skin water retention function, resulting in dry skin, which is easily stimulated by changes in cold and heat in t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/439A61P17/04A61P25/00
CPCA61P17/04A61P25/00A61K31/439A61K31/55A61K9/2077A61K9/2054A61K9/2018A61K9/5026A61K9/0019A61K47/02A61K9/7069A61K47/44A61K9/08A61K9/2013A61K9/2059A61K9/28A61K9/4858A61K9/4866A61K9/4891A61K9/7053
Inventor 刘先国李彪吴琼粉
Owner YUNNAN HAOPY PHARM LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap